DUBLIN--(BUSINESS WIRE)--The "Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030" report has been added to Research and Markets' offering.
The Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017-2030' report provides a comprehensive study on the current landscape and the future outlook of the growing pipeline of products (therapeutics and diagnostics) in this area.
The rising popularity and potential within this domain can be correlated with the exponential increase in the number of citations of the term microbiome on PubMed, the popular scientific literature resource; the number increased from 959 citations in 2003 to 33,809 citations in the first half of 2017.
While the field has captured the interest of several companies and investors alike, no approved microbiome drugs are yet available in the market; FMT is currently the only commercially available microbiome based therapy. In addition, a few microbiome diagnostic tests are commercially available for the detection of gastrointestinal (GI) disorders and inflammatory diseases. Having said that, the development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories in the foreseen future.
The report is primarily focused on prescription drugs, probiotic drugs and prebiotic drugs, which are being developed in this domain. In addition, we have captured FMT products and screening/diagnostic tests that are already available/under development. During the course of our study, we identified over 170 microbiome therapeutics and close to 25 microbiome diagnostics across various stages of development; majority of the therapeutic products are currently in early phases of development.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Competitive Landscape
5. Company Profiles
6. Microbiome Diagnostics
7. Fecal Microbiota Therapy
8. Big Data And Microbiome Therapeutics
9. Key Therapeutic Areas
10. Venture Capital Funding
11. Partnerships And Collaborations
12. Contract Services For Microbiome Therapeutics
13. Market Size And Opportunity Analysis
14. Key Insights
15. Conclusion
16. Interview Transcripts
17. Appendix: List Of Consumer Products, Medical Foods And Supplements
18. Appendix: Tabulated Data
19. Appendix: List Of Companies And Organizations
For more information about this report visit https://www.researchandmarkets.com/research/ls8jkv/microbiome
